08 May 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe Psoriasis
Yi Zhou123ACDE, Yantao Ding123BCDE, Mengxing Cui4F, Yuanjing Zhang123BCD, Mengwei Wang32B, Feiran Zhou5F, Yi Su6F, Bo Liang123ACDG*, Fusheng Zhou123ACDDOI: 10.12659/MSM.943360
Med Sci Monit 2024; 30:e943360
Table 1 Clinical characteristics of patients with psoriasis on methotrexate therapy.
| N | Age | Sex (Male: Female) | BMI | Smoking (%) | |
|---|---|---|---|---|---|
| All samples | |||||
| Batch 1 | 50 | 42.7±11.4 | 36: 14 | 24.1±3.7 | 23 (46%) |
| Batch 2 | 46 | 43.5±12.8 | 32: 14 | 24.4±3.0 | 17 (37.0%) |
| MTX Responser (RE) | |||||
| Batch 1 | 10 | 46.2±9.6 | 6: 4 | 24.6±3.4 | 5 (50%) |
| Batch 2 | 24 | 46.0±12.3 | 16: 8 | 24.0±2.7 | 10 (41.7%) |
| MTX Non-responser (NR) | |||||
| Batch 1 | 40 | 41.9±10.9 | 30: 10 | 23.9±3.8 | 18 (45%) |
| Batch 2 | 22 | 40.9±13.0 | 16: 6 | 24.9±3.3 | 7 (31.8%) |
| All samples | |||||
| Batch 1 | 50 | 30.9±13.4 | 11.8±9.7 | 21.2±14.0 | 118.2±21.6 |
| Batch 2 | 46 | 31.1±13.2 | 12.4±11.5 | 12.4±6.8 | 124.9±22.3 |
| MTX Responser (RE) | |||||
| Batch 1 | 10 | 28.9±20.3 | 4.4±2.9 | 83.8±6.3% | 119.5±13.6 |
| Batch 2 | 24 | 14.5±7.4 | 2.7±2.0 | 82.4±6.4% | 116.5±15.6 |
| MTX Non-responser (NR) | |||||
| Batch 1 | 40 | 19.6±12.1 | 16.3±9.0 | 9.7±34.9% | 117.8±23.3 |
| Batch 2 | 22 | 10.1±5.5 | 8.9±5.6 | 8.0±38.8% | 134.1 ±25.2 |
| PASI – psoriasis area and severity index; BMI – body mass index; RE – PASI improved by at least 75%; NR – PASI improved by less than 75%. | |||||